I was in CTSO as well and you conveniently forgot to mention that the stock actually crossed over closer to $5.50 in December of 2014 and rose to $14.00 in mid-March before the March 31st 10-q & conference call took some life out of the party-
And it continued to stay above $7.00 for weeks afterwards. So if you didn't make money, your either stupid or greedy - or likely both-
R/s is needed. Look at all the good news that has come. With all the good news, especially the phase 3 combo data for HIV should have put us at least at $2 per share. the OTC is built on NITE and CANT shorting stocks and manipulating share price.
Most other biotechs that did a r/s were not this far along. They were only in phase 1 or phase 2 that I have seen in the past. LJPC uplisted when it was only in a phase 2. The thing is that Cytodyn has already passed a phase 3 combo for HIV that's huge. I think as soon as it gets on the NASDAQ institutions may buy in. It has to happen otherwise not even BLA news is going to move the stock on the OTC.
Market Data 
Markets 
AI
